292 Hardiman: Role of research in developing anthrax countermeasures late cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun. 1988;56(5):1066-9. 36. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocy- tosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol. 2003;160(3):321-8. 37. Zhang S, Cunningham K, Collier RJ. Anthrax protective antigen: efficiency of translocation is independent of the number of ligands bound to the prepore. Biochemistry. 2004;43(20):6339-43. 38. Krantz BA, Finkelstein A, Collier RJ. Protein translocation through the anthrax toxin trans- membrane pore is driven by a proton gradi- ent. J Mol Biol. 2006;355(5):968-79. 39. Krantz BA, Trivedi AD, Cunningham K, Christensen KA, Collier RJ. Acid-induced unfolding of the amino-terminal domains of the lethal and edema factors of anthrax toxin. J Mol Biol. 2004;344(3):739-56. 40. Feld GK, Thoren KL, Kintzer AF, Sterling HJ, Tang II, Greenberg SG, et al. Structural basis for the unfolding of anthrax lethal fac- tor by protective antigen oligomers. Nat Struct Mol Biol. 2010;17(11):1383-90. 41. Bragg TS, Robertson DL. Nucleotide se- quence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene. 1989;81(1):45-54. 42. Quinn CP, Singh Y, Klimpel KR, Leppla SH. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J Biol Chem. 1991;266(30):20124-30. 43. Arora N, Leppla SH. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mam- malian cells. Infect Immun. 1994;62(11):4955- 61. 44. Tamayo AG, Slater L, Taylor-Parker J, Bharti A, Harrison R, Hung DT, et al. GRP78(BiP) facil- itates the cytosolic delivery of anthrax lethal fac- tor (LF) in vivo and functions as an unfoldase in vitro. Mol Microbiol. 2011;81(5):1390-401. 45. Tamayo AG, Bharti A, Trujillo C, Harrison R, Murphy JR. COPI coatomer complex pro- teins facilitate the translocation of anthrax lethal factor across vesicular membranes in vitro. Proc Natl Acad Sci USA. 2008;105(13):5254-9. 46. Dmochewitz L, Lillich M, Kaiser E, Jennings LD, Lang AE, Buchner J, et al. Role of CypA and Hsp90 in membrane translocation medi- ated by anthrax protective antigen. Cell Mi- crobiol. 2011;13(3):359-73. 47. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angio- genic therapy. Front Biosci. 2011;16:1574-88. 48. Singh Y, Klimpel KR, Quinn CP, Chaudhary VK, Leppla SH. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J Biol Chem. 1991;266(23):15493-7. 49. LeMaistre CF, Meneghetti C, Howes L, Os- borne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994;32(1):97-103. 50. Cawley DB, Herschman HR, Gilliland DG, Collier RJ. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell. 1980;22(2 Pt 2):563-70. 51. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related inter- leukin-2 fusion protein. Protein Eng. 1987;1(6):493-8. 52. FDA Approval for Denileukin Diftitox [In- ternet]. [cited 2012 Mar 19]. Available from: http://www.cancer.gov/cancertopics/drug- info/fda-denileukindiftitox. 53. Ratts R, Trujillo C, Bharti A, vanderSpek J, Harrison R, Murphy JR. A conserved motif in transmembrane helix 1 of diphtheria toxin me- diates catalytic domain delivery to the cytosol. Proc Natl Acad Sci USA. 2005;102(43):15635- 40. 54. Blanke SR, Milne JC, Benson EL, Collier RJ. Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Proc Natl Acad Sci USA. 1996;93(16):8437-42. 55. Gaudioso J, Rivera SB, Caskey S, Salerno RM. Laboratory Biosecurity: A Survey of the U.S. Bioscience Community. Applied Biosafety. 2006;11(3):138-43. 56. Hirschberg R, La Montagne J, Fauci AS. Biomedical research—an integral compo- nent of national security. N Engl J Med. 2004;350(21):2119-21. 57. Dias MB, Reyes-Gonzalez L, Veloso FM, Casman EA. Effects of the USA PATRIOT Act and the 2002 Bioterrorism Preparedness Act on select agent research in the United States. Proc Natl Acad Sci USA. 2010;107(21):9556- 61.